NUVB (Nuvation Bio) Tariff Resilience Score: 6/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NUVB Nuvation Bio Inc NUVB
33 GF Score
Price $5.64
! 3 Warning Signs
View Full Analysis

What is Nuvation Bio Tariff Resilience Score?

Nuvation Bio NUVB -4.41% 33 Tariff Resilience Score is 6 as of Jul. 16, 2026. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, Nuvation Bio ranks better than 75.99% on this metric.

Nuvation Bio has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Nuvation Bio has Nuvation Bio Inc has moderate resilience due to its focus on biotechnology, which often benefits from tariff exemptions. The company has a diversified supply chain and can leverage partnerships to mitigate potential tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Nuvation Bio might have Average Resilient.

Nuvation Bio  (NYSE:NUVB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Nuvation Bio Tariff Resilience Score Related Terms

NUVB vs VRDN, STOK, ATAI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Nuvation Bio's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Tariff Resilience Score falls into.


NUVB
33GF Score
Nuvation Bio Inc NUVB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Nuvation Bio (NUVB) has a Tariff Resilience Score of 6 as of Jul. 16, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Nuvation Bio ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Nuvation Bio's Tariff Resilience Score too high?
Nuvation Bio's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Nuvation Bio's value of 6 is 50% above this industry median. Based on the distribution chart, Nuvation Bio ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Tariff Resilience Score compare to VRDN and STOK?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #329 out of 1370 companies for Tariff Resilience Score. This places Nuvation Bio in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Nuvation Bio's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Tariff Resilience Score is 6 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvation Bio Business Description

Other Exchanges 1E30:Germany
Address 1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score

Get the complete analysis for NUVB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.64
Price